MAPT and Alzheimer disease: PE seems to promote a neuroprotective effect in patients with AD, since it was shown to induce positive changes in some of the biomarkers related to the pathophysiological processes of the disease, such as the reduced concentrations of Aβ peptides, tau protein, and pro-inflammatory cytokines, or increase the release of BDNF and anti-inflammatory cytokines.